To improve image quality and CT number accuracy of fast-scan low-dose cone-beam computed tomography (CBCT) through a deep-learning convolutional neural network (CNN) methodology for head-and-neck (HN) radiotherapy. Fifty-five paired CBCT and CT images from HN patients were retrospectively analysed. Among them, 15 patients underwent adaptive replanning during treatment, thus had same-day CT/CBCT pairs. The remaining 40 patients (post-operative) had paired planning CT and 1st fraction CBCT images with minimal anatomic changes. A 2D U-Net architecture with 27-layers in 5 depths was built for the CNN. CNN training was performed using data from 40 post-operative HN patients with 2080 paired CT/CBCT slices. Validation and test datasets include 5 same-day datasets with 260 slice pairs and 10 same-day datasets with 520 slice pairs, respectively. To examine the impact of differences in training dataset selection and network performance as a function of training data size, additional networks were trained using 30, 40 and 50 datasets. Image quality of enhanced CBCT images were quantitatively compared against the CT image using mean absolute error (MAE) of Hounsfield units (HU), signal-to-noise ratio (SNR) and structural similarity (SSIM). Enhanced CBCT images reduced artifact distortion and improved soft tissue contrast. Networks trained with 40 datasets had imaging performance comparable to those trained with 50 datasets and outperformed those trained with 30 datasets. Comparison of CBCT and enhanced CBCT images demonstrated improvement in average MAE from 172.73 to 49.28 HU, SNR from 8.27 to 14.25 dB, and SSIM from 0.42 to 0.85. The image processing time is 2 s per patient using a NVIDIA GeForce GTX 1080 Ti GPU. The proposed deep-leaning methodology was fast and effective for image quality enhancement of fast-scan low-dose CBCT. This method has potential to support fast online-adaptive re-planning for HN cancer patients.

PURPOSE:The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve.

Background: Breast imaging technology plays an important role in breast cancer planning and treatment. Recently, three-dimensional (3D) printing technology has become a trending issue in phantom constructions for medical applications, with its advantages of being customizable and cost-efficient. However, there is no current practice in the field of multipurpose breast phantom for quality control (QC) in multi-modalities imaging. The purpose of this study was to fabricate a multipurpose breast phantom with tissue-equivalent materials via a 3D printing technique for QC in multi-modalities imaging. Methods: We used polyvinyl chloride (PVC) based materials and a 3D printing technique to construct a breast phantom. The phantom incorporates structures imaged in the female breast such as microcalcifications, fiber lesions, and tumors with different sizes. Moreover, the phantom was used to assess the sensitivity of lesion detection, depth resolution, and detectability thresholds with different imaging modalities. Phantom tissue equivalent properties were determined using computed tomography (CT) attenuation [Hounsfield unit (HU)] and magnetic resonance imaging (MRI) relaxation times. Results: The 3D-printed breast phantom had an average background value of 36.2 HU, which is close to that of glandular breast tissue (40 HU). T1 and T2 relaxation times had an average relaxation time of 206.81±17.50 and 20.22±5.74 ms, respectively. Mammographic imaging had improved detection of microcalcification compared with ultrasound and MRI with multiple sequences [T1WI, T2WI and short inversion time inversion recovery (STIR)]. Soft-tissue lesion detection and cylindrical tumor contrast were superior with mammography and MRI compared to ultrasound. Hemispherical tumor detection was similar regardless of the imaging modality used. Conclusions: We developed a multipurpose breast phantom using a 3D printing technique and determined its value for multi-modal breast imaging studies.

Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating locally advanced and metastatic cervical cancer (CC). Immunotherapy is emerging as a novel therapeutic approach in this disease for which the causative agent, human papillomavirus (HPV), has dynamic, complex immunomodulatory effects. This review explores the biologic rational of immuno-oncology in the treatment of CC and discusses the initial clinical efficacy, ongoing clinical trials, and rationale for combined multimodal treatment approaches for locally advanced and recurrent/metastatic CC. The utility of immune checkpoint inhibitors is explored, including anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-L1. Preliminary data supporting the combination of radiotherapy and immunotherapy and areas of active drug development for CC are also reviewed.